Clinical trials: CINV
Chemotherapy Induced Nausea and Vomiting
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients…
- Trial name
- NCT06065722
- Testing
- Akynzeo
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Simon Williamson Clinic
Chemotherapy-Induced Nausea and Vomiting (CINV)
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.
- Trial name
- NCT01111851
- Testing
- Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.